Detalles de la búsqueda
1.
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
Oncologist
; 29(6): e843-e847, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38597608
2.
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Lancet Oncol
; 21(12): 1589-1601, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125909
3.
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
JCO Precis Oncol
; 7: e2300218, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37677122
4.
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
J Clin Oncol
; 40(21): 2295-2306, 2022 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35658002
5.
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
Clin Lung Cancer
; 22(3): 178-186, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33358401
6.
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(9): 1368-1377, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264316
7.
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
J Immunother Cancer
; 9(8)2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34429332
8.
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Clin Lung Cancer
; 22(3): 170-177, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33221175
9.
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
J Thorac Oncol
; 14(10): 1853-1859, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31302234
10.
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
J Thorac Oncol
; 14(10): 1847-1852, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31195180
11.
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
J Thorac Oncol
; 14(10): 1839-1846, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31158500
Resultados
1 -
11
de 11
1
Próxima >
>>